Validation of a direct-to-PCR COVID-19 detection protocol utilizing mechanical homogenization: A model for reducing resources needed for accurate testing.
COVID-19
/ diagnosis
COVID-19 Nucleic Acid Testing
/ instrumentation
Feasibility Studies
Humans
Nasopharynx
/ virology
Oropharynx
/ virology
Prospective Studies
RNA, Viral
/ genetics
Real-Time Polymerase Chain Reaction
SARS-CoV-2
/ genetics
Sensitivity and Specificity
Specimen Handling
/ instrumentation
Workflow
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
05
2021
accepted:
03
08
2021
entrez:
18
8
2021
pubmed:
19
8
2021
medline:
26
8
2021
Statut:
epublish
Résumé
Efficient and effective viral detection methodologies are a critical piece in the global response to COVID-19, with PCR-based nasopharyngeal and oropharyngeal swab testing serving as the current gold standard. With over 100 million confirmed cases globally, the supply chains supporting these PCR testing efforts are under a tremendous amount of stress, driving the need for innovative and accurate diagnostic solutions. Herein, the utility of a direct-to-PCR method of SARS-CoV-2 detection grounded in mechanical homogenization is examined for reducing resources needed for testing while maintaining a comparable sensitivity to the current gold standard workflow of nasopharyngeal and oropharyngeal swab testing. In a head-to-head comparison of 30 patient samples, this initial clinical validation study of the proposed homogenization-based workflow demonstrated significant agreeability with the current extraction-based method utilized while cutting the total resources needed in half.
Identifiants
pubmed: 34407126
doi: 10.1371/journal.pone.0256316
pii: PONE-D-21-16323
pmc: PMC8372900
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0256316Subventions
Organisme : Medical Research Council
ID : MC_PC_19026
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12014/9
Pays : United Kingdom
Déclaration de conflit d'intérêts
Z.P.M., C.M.P., G.L.R., and R.J.N. disclose that they are all currently employed by Omni International Inc, A PerkinElmer Company in some capacity, however, none of the authors have any personal financial interests in the success or failure of the company. R.J.N. also discloses that he is the founder and CEO of Jeevan BioSciences with personal financial interests in its success or failure. All authors declare that their our competing interests do not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
N Engl J Med. 2020 Jul 16;383(3):e14
pubmed: 32469477
Virol J. 2020 Aug 25;17(1):129
pubmed: 32843049
Ann Intern Med. 2020 Jun 2;172(11):726-734
pubmed: 32282894
Nat Commun. 2021 Mar 5;12(1):1467
pubmed: 33674580
J Family Med Prim Care. 2020 Aug 25;9(8):3838-3842
pubmed: 33110776
J Clin Microbiol. 2020 Apr 23;58(5):
pubmed: 32102856
Pharmacotherapy. 2020 Aug;40(8):857-868
pubmed: 32643218
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
JAMA. 2020 Dec 1;324(21):2153-2154
pubmed: 33185688
Mo Med. 2020 May-Jun;117(3):184-195
pubmed: 32636542
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Front Med (Lausanne). 2021 Feb 17;8:627679
pubmed: 33681254